Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 11:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Sevelamer and Secondary Hyperparathyroidism in Chronic Kidney Disease

NCT01191762
Conditions
Hyperparathyroidism, Chronic Kidney Disease
Interventions
sevelamer carbonate, placebo
Drug
Lead sponsor
Kenneth R. Phelps, M.D.
Individual
Eligibility
18 Years to 120 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Albany, New York
Conditions
Secondary Hyperparathyroidism
Interventions
Sensipar (Cinacalcet HCl)
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
16
States / cities
Phoenix, Arizona • Los Angeles, California • Denver, Colorado + 13 more
Conditions
Vitamin D Insufficiency, Secondary Hyperparathyroidism
Interventions
CTAP101 Capsules
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Cypress, California
Conditions
Secondary Hyperparathyroidism
Interventions
Hectorol® (doxercalciferol capsules), doxercalciferol capsules, Hectorol®, doxercalciferol capsules, Hectorol® capsules
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
8
States / cities
Hot Springs, Arkansas • Downey, California • Tarzana, California + 5 more
Conditions
Chronic Kidney Disease, Hyperparathyroidism, Secondary
Interventions
Cinacalcet hydrochloride, Standard of Care
Drug
Lead sponsor
Amgen
Industry
Eligibility
28 Days to 2189 Days
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
17
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 14 more
Terminated Phase 1Phase 2 Interventional Results available

Cinacalcet to Treat Hypercalcemia in Renal Transplant Recipients

NCT00415584
Conditions
Secondary Hyperparathyroidism, Hypercalcemia
Interventions
Cinacalcet HCl
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
The Bronx, New York
Conditions
Hyperparathyroidism, Secondary
Interventions
Etelcalcetide
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
40
States / cities
Alhambra, California • Azusa, California • Bakersfield, California + 37 more
Conditions
CKD Stage 3, CKD Stage 4, Secondary Hyperparathyroidism, VDI
Interventions
CTAP101
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
1 Month to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
5
States / cities
Kansas City, Missouri • Columbus, Ohio • Philadelphia, Pennsylvania + 2 more
Conditions
Secondary Hyperparathyroidism Due to Renal Causes, Vitamin D Insufficiency, CKD Stage 3, CKD Stage 4
Interventions
Calcifediol Oral Capsule, Calcifediol Oral Product, Cholecalciferol, Paricalcitol Oral Capsule
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
3
States / cities
Garden Grove, California • Chicago, Illinois • West Bend, Wisconsin
Conditions
Chronic Kidney Disease, Secondary Hyperparathyroidism
Interventions
Cinacalcet HCl, Standard of Care
Drug · Dietary Supplement
Lead sponsor
Amgen
Industry
Eligibility
6 Years to 17 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
26
States / cities
Los Angeles, California • Wilmington, Delaware • Atlanta, Georgia + 22 more
Conditions
Renal Osteodystrophy, Chronic Kidney Diseases, CKD-MBD, Bone Turnover Rate Disorder, Secondary Hyperparathyroidism
Interventions
miRNAseq analysis, Standard treatment for bone disorder
Procedure · Drug
Lead sponsor
Thomas Nickolas
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Completed Not applicable Interventional Results available

Oral Paricalcitol in Kidney Transplant Recipients

NCT00587158
Conditions
Transplant; Failure, Kidney, Renal Disease, End Stage, Hyperparathyroidism, Secondary
Interventions
Paricalcitol, Corticosteroid Avoidance Immune Suppression Protocol
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Conditions
Chronic Kidney Disease, Secondary Hyperparathyroidism, Hemodialysis
Interventions
Paricalcitol, Cinacalcet
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
30
States / cities
Tempe, Arizona • Chula Vista, California • Los Angeles, California + 22 more
Conditions
Chronic Kidney Disease, Vitamin D Deficiency
Interventions
Cholecalciferol, Placebo
Drug
Lead sponsor
Atlanta VA Medical Center
Federal
Eligibility
18 Years to 85 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Hyperparathyroidism, Secondary
Interventions
doxercalciferol
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Breast Cancer, Prostate Cancer, Bone Neoplasms, Hypocalcemia, Hyperparathyroidism, Secondary
Interventions
CTAP101 Capsules
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
6
States / cities
Long Beach, California • Miami, Florida • Evergreen Park, Illinois + 3 more
Conditions
Coronary Artery Disease, Chronic Kidney Disease, Hypovitaminosis D, Secondary Hyperparathyroidism
Interventions
paricalcitol, placebo
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Secondary Hyperparathyroidism Due to Renal Causes, Chronic Kidney Diseases, Vitamin D Deficiency, Stage 5 Chronic Kidney Disease
Interventions
Calcifediol Oral Capsule, Placebo oral capsule
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
18
States / cities
Peoria, Arizona • Phoenix, Arizona • Cypress, California + 13 more
Conditions
Chronic Kidney Disease
Interventions
Calcium acetate, Lanthanum Carbonate, Sevelamer Carbonate, Placebo
Drug
Lead sponsor
Denver Nephrologists, P.C.
Other
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Denver, Colorado
Active, not recruiting Phase 2 Interventional

DePTH: De-emphasize PTH

NCT06288451
Conditions
Kidney Failure, Chronic, Chronic Kidney Disease-Mineral and Bone Disorder
Interventions
Oral calcitriol with cinacalcet rescue, IV activated vitamin D
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Secondary Hyperparathyroidism
Interventions
Hectorol (doxercalciferol injection), Zemplar (Paricalcitol injection)
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Hyperphosphatemia
Interventions
Niacinamide
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Chronic Kidney Disease, Hyperparathyroidism, Secondary, Secondary Hyperparathyroidism
Interventions
Cinacalcet
Drug
Lead sponsor
Amgen
Industry
Eligibility
28 Days to 2190 Days
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
4
States / cities
Los Angeles, California • San Francisco, California • Louisville, Kentucky + 1 more
Completed Phase 2 Interventional Results available

The Effect of Etelcalcetide on CKD-MBD

NCT03960437
Conditions
Chronic Kidney Disease Mineral and Bone Disorder, Renal Osteodystrophy, Vascular Calcification, Hyperparathyroidism; Secondary, Renal
Interventions
Etelcalcetide
Drug
Lead sponsor
Thomas Nickolas, MD MS
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
New York, New York